Everolimus LUNA



Everolimus LUNA Everolimus LUNA PRELIMINARY SCORE **SCORE CURATIVE CURATIVE** Overall Survival / Disease-Free Survival / Pathological Complete Response **NON-CURATIVE NON-CURATIVE** Overall Survival **ADJUSTMENTS** Quality of life Progression-Free Survival Not qualified for an ESMO-MCBS credit Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Serious and disabling adverse effects Overall Response Rate / Duration of Response More serious and disabling adverse events observed Overall Survival / Disease-Free Survival / Pathological Complete Response INFORMATION Other adjustments Tumour type: Endocrine Tumours Therapeutic Indication: Advanced carcinoids of the lung and thymus Experimental Arm: Everolimus + Pasireotide Control Arm: Single arm



© 2024 | European Society for Medical Oncology | ESMO - MCBS 1.1 | All rights reserved worldwide.